Drug Price Transparency Act of 2021
United States117th CongressS-1523Senate
Updated: Apr 29, 2021
Summary
Drug Price Transparency Act of 2021 This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Bill texts
All available records shown.
Timeline
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Senate
Introduced in Senate
All available records shown.